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Abstract
Melanoma is an often fatal form of skin cancer which is remarkably resistant against radio- and chemotherapy. Even new
strategies that target RAS/RAF signaling and display unprecedented efficacy are characterized by resistance mechanisms.
The targeting of survival pathways would be an attractive alternative strategy, if tumor-specific cell death can be achieved.
Bcl-2 proteins play a central role in regulating survival of tumor cells. In this study, we systematically investigated the
relevance of antiapoptotic Bcl-2 proteins, i.e., Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1, in melanoma cell lines and non-malignant
cells using RNAi. We found that melanoma cells required the presence of specific antiapoptotic Bcl-2 proteins: Inhibition of
Mcl-1 and A1 strongly induced cell death in some melanoma cell lines, whereas non-malignant cells, i.e., primary human
fibroblasts or keratinocytes were not affected. This specific sensitivity of melanoma cells was further enhanced by the
combined inhibition of Mcl-1 and A1 and resulted in 60% to 80% cell death in all melanoma cell lines tested. This treatment
was successfully combined with chemotherapy, which killed a substantial proportion of cells that survived Mcl-1 and A1
inhibition. Together, these results identify antiapoptotic proteins on which specifically melanoma cells rely on and, thus,
provide a basis for the development of new Bcl-2 protein-targeting therapies.
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Introduction
Melanoma is one of the deadliest types of skin cancer with
strongly rising incidence. Due to its therapy resistance in advanced
stages, melanoma is the skin cancer with the highest mortality.
Fewer than 20% of melanoma patients respond to chemotherapy,
which does not prolong the survival of late stage melanoma
patients [1,2]. Recent studies indicate that targeting the MAP
kinase signaling pathway, which is commonly activated in
melanoma, represents an important new therapeutic approach.
Inhibitors that specifically target the most common V600E mutant
form of BRAF displayed a remarkable tumor response even in
advanced melanoma [3]. However, there is evidence that
melanoma cells can become resistant to RAF inhibition [4,5].
The targeted activation of apoptotic pathways may be an
alternative antitumor strategy and may be valuable to overcome
de novo or acquired resistance to conventional chemotherapy or
MAP kinase inhibition. Apoptosis can be initiated via two
pathways, the mitochondrial and the death receptor-mediated
pathway [6]. Critical for regulation of the mitochondrial apoptosis
pathway are molecules of the Bcl-2 family [7]. This family consists
of antiapoptotic proteins like Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1,
and proapoptotic proteins like Bax, Bak, and the BH3-only
subgroup. A shift in the balance of antiapoptotic Bcl-2 proteins
and proapoptotic BH3-only proteins results in activation of Bax
and Bak at the outer mitochondrial membrane, which leads to
permeabilization of the outer mitochondrial membrane and to the
release of cytochrome c into the cytosol. Cytosolic cytochrome c
leads to the formation of complexes, called apoptosomes, which
results in caspase activation and cell death. The molecular
mechanisms by which antiapoptotic Bcl-2 proteins and proapop-
totic BH3-only proteins regulate Bax or Bak activation is not
entirely clear [8,9].
The group of antiapoptotic Bcl-2 proteins consists of five
members, i.e., Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1. The
expression level and relevance for survival of each antiapoptotic
member varies between different cell lineages. Antiapoptotic
proteins can promote survival and, accordingly, the expression
or the activity of antiapoptotic proteins can be increased in cancer.
In addition, cellular stress in tumors, e.g., generated by genomic
alterations, exaggerated proliferation, or insufficient nutrition can
result in the requirement of antiapoptotic proteins for tumor cell
survival. This situation, termed synthetic lethality, can make tumor
cells vulnerable and offers the opportunity for therapeutic
intervention [10,11]. Indeed, several synthetic inhibitors, the so-
called BH3 mimetics, have been developed that counteract the
activity of antiapoptotic proteins. These molecules inhibit certain
members of the antiapoptotic Bcl-2 subgroup and, therefore,
display different activity in each cell type [12].
In this study, we systematically investigated the relevance of
antiapoptotic Bcl-2 proteins in melanoma cell lines utilizing RNA
interference. In addition, primary human fibroblasts from skin
were studied in order to identify those antiapoptotic Bcl-2 proteins
whose loss specifically affects melanoma cells while sparing non-
malignant cells. It was found that melanoma cell lines – in contrast
to non-malignant fibroblasts - required specific antiapoptotic Bcl-2
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30821proteins for survival. Inhibition of Mcl-1 and A1 resulted in cell
death of melanoma cell lines and targeting both antiapoptotic Bcl-
2 proteins simultaneously enhanced cell death to 80% whereas
non-malignant cells remained unaffected. In addition, cell death
induction could be further increased by exposure to chemother-
apeutic drugs.
Results
Expression of antiapoptotic Bcl-2 proteins in melanoma
Expression levels of antiapoptotic Bcl-2 proteins were analyzed
by immunoblotting. Because sensitivity of commercial A1
antibodies was found to be not sufficient for detection, expression
levels of A1 were analyzed on RNA level. Compared to primary
human keratinocytes and fibroblasts, primary human melanocytes
expressed lower levels of Bcl-xL and Mcl-1 whereas levels of Bcl-2
and A1 were higher (Figure 1A and 1D). This melanocytic
expression signature was confirmed in several donors (Figure 1B).
Next, melanoma cell lines of non-invasive, invasive, and metastatic
origin were analyzed. The expression pattern was clearly altered to
that of melanocytes (Figure 1C and 1D). Some melanoma cell
lines, e.g., WM793, WM1232, or WM1158, expressed high levels
of Bcl-xL suggesting a survival advantage, however this was not
consistent throughout the panel and low Bcl-xL levels were
observed as well (e.g., in 1205Lu). In addition, antiapoptotic Bcl-2
proteins like Bcl-2, Bcl-w, or A1, which were strongly expressed in
melanocytes, were only expressed at low levels in some melanoma
cell lines, such as WM3211, WM1158, and WM1232.
These results suggest that melanocytes express a characteristic
expression pattern of antiapoptotic Bcl-2 proteins, which is clearly
altered in melanoma cells. In contrast to melanocytes, the
expression profile in melanoma cells was inconsistent among
Figure 1. Expression of antiapoptotic Bcl-2 proteins in non-malignant skin cells and melanoma cell lines. (A) Expression of Bcl-2, Bcl-xL,
Bcl-w, and Mcl-1 protein in primary human fibroblasts, keratinocytes, and melanocytes was analyzed by immunoblotting. For each cell type, 2 donors
are shown. (B) Expression of Bcl-2, Bcl-xL, Bcl-w and Mcl-1 protein in melanocytes isolated from 4 donors. (C) Expression of Bcl-2, Bcl-xL, Bcl-w and
Mcl-1 protein in melanoma cell lines of different progression levels. Blot is representative for 2 independent experiments. (D) Levels of A1 mRNA were
measured by quantitative RT-PCR. Mean +/2 SD of 3 donors is shown for non-malignant cells, mean +/2 SD of 3 cell passages is shown for
melanoma cell lines. b-actin served as loading control in immunoblots. The same protein sample of melanocytes from donor #2 was loaded on all
gels as a reference to allow the comparison of expression levels among the immunoblots shown in A, B, and C. RGP: radial-growth phase (non-
invasive); VGP: vertical growth phase (invasive).
doi:10.1371/journal.pone.0030821.g001
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antiapoptotic Bcl-2 proteins was observed in melanoma cell lines,
which would point towards a pro-survival role.
Inhibition of Mcl-1 or A1 leads to cell death specifically in
melanoma cell lines
Next, the relevance of antiapoptotic Bcl-2 proteins for
melanoma cell survival was assessed by silencing them utilizing
RNA interference. Effects caused by silencing of Bcl-2, Bcl-xL,
Bcl-w, Mcl-1, or A1 were analyzed in the metastatic melanoma
cell line 1205Lu. In addition, non-malignant cells were analyzed in
order to dissect Bcl-2 proteins that are specifically important for
melanoma survival. For this, primary human fibroblasts instead of
melanocytes were used as a non-malignant reference. Fibroblasts
represent a more prevalent cell type and, in a therapeutic
perspective, unspecific cell death is expected to be more serious
in ubiquitous cell types than in melanocytes. Furthermore,
transfection efficacy of siRNAs is insufficient in melanocytes
resulting in inefficient inhibition. ShRNA expression is applicable
in melanocytes, e.g., by utilizing lentiviral shRNA-encoding
constructs, however, in general, we observe lower silencing
efficacies of shRNAs compared to siRNAs. Therefore, it is unlikely
to generate the same inhibition efficacies in melanocytes as in
melanoma cells. In fibroblasts and melanoma cells, the applied
siRNAs efficiently abrogated expression of the respective Bcl-2
molecule (Figure 2A and B). The effect of targeting antiapoptotic
Bcl-2 proteins on cell death was analyzed 3 days after siRNA
transfection by staining with Annexin V and propidium iodide. In
primary fibroblasts, none of the targeted Bcl-2 proteins led to
induction of cell death at this time point (Figure 2C and E; upper
panel). In melanoma cells, however, significant apoptosis induction
was observed when Mcl-1 or A1 were inhibited: Cell death
increased from 8% in control siRNA-treated cells to 40% in Mcl-
1-inhibited or 30% in A1-inhibited cells (Figure 2D and E; lower
panel). A slight increase in cell death was also observed upon
targeting of Bcl-2, Bcl-xL, or Bcl-w. Because 3 melanoma cell lines
expressed increased amounts of Bcl-xL compared to melanocytes
(Figure 1C), we tested whether these cells may be dependent on
Bcl-xL. However inhibition of Bcl-xL affected cell death only
slightly in WM1232, a cell line with high Bcl-xL levels, (data not
shown).
Together, these data show that silencing of individual Bcl-2
proteins does not induce cell death in non-malignant fibroblasts. In
contrast, melanoma cells were found to be dependent on the
presence of specific antiapoptotic proteins: Inhibition of Mcl-1 or
A1 caused significant cell death without further apoptotic stimulus.
Co-inhibition of Mcl-1 and A1 results in efficient cell
death induction of melanoma cell lines without affecting
primary human skin cells
The results suggested that targeting of the appropriate Bcl-2
proteins, i.e., Mcl-1 or A1, represents a strategy to specifically
induce apoptosis in melanoma. A consistent, but not significant
increase was also observed when Bcl-2, Bcl-xL, and Bcl-w were
targeted in 1205Lu melanoma cells (Figure 2D). We, therefore,
tested whether cell death can be enhanced in a tumor-specific
manner by targeting additional antiapoptotic Bcl-2 proteins. For
this, the BH3 mimetic ABT-737 was used, which inactivates Bcl-
2, Bcl-xL, and Bcl-w [13]. In the presence of A1 inhibition, ABT-
737 increased cell death to 50% and in the presence of Mcl-1
inhibition to 80%, respectively (Figure 3A; right panel). However
in non-malignant fibroblasts, a similar increase of cell death was
observed, indicating that simultaneous inactivation of Bcl-2, Bcl-
xL, Bcl-w, together with Mcl-1 leads to apoptosis in several cell
types (Figure 3A; left panel). As targeting of several antiapoptotic
proteins simultaneously was found to enhance apoptosis, we
tested whether inhibition of one antiapoptotic Bcl-2 protein
together with either Mcl-1 or A1 is able to enhance apoptosis
induction in a tumor-specific manner. Using two siRNAs
simultaneously, Bcl-2, Bcl-xL, or Bcl-w was individually silenced
together with Mcl-1 or A1. In addition, co-inhibition of Mcl-1
and A1 was investigated. In the presence of siRNA-mediated
inhibition of Mcl-1 or A1, co-transfection of Bcl-2-, Bcl-xL-, or
Bcl-w-specific siRNA resulted in inhibition of the respective two
molecules (Figure 3B).
Next, cell death was analyzed. Non-malignant fibroblasts
survived the simultaneous inhibition of A1 and Bcl-2, Bcl-xL, or
Bcl-w, respectively. Similarly, these cells were not affected by
inhibition of Mcl-1 together with Bcl-2 or Bcl-w, respectively,
while co-inhibition of Mcl-1 and Bcl-xL strongly induced cell
death (Figure 3C). In 1205Lu melanoma cells, cell death induction
was observed throughout most combinations, which was expected
since inhibition of Mcl-1 or A1 alone already resulted in cell death
(Figure 3D). As described in Material and Methods, transfected
siRNA amounts in single inhibition experiments were equal to the
one in double inhibition experiments allowing the comparison of
single versus double inhibition. Cell death in response to Mcl-1
inhibition (around 40% as seen in Figure 2D) was enhanced by
additional targeting of Bcl-2, Bcl-xL, Bcl-w, and A1 (50–80%,
Figure 3D), respectively. Most strikingly, cell death was induced by
Bcl-xL/Mcl-1 co-inhibition, however this was also observed in
non-malignant cells (Figure 3C and D) indicating that this
combination does not allow cell death induction in a tumor-
specific manner.
Among the tumor-specific combinations, simultaneous inhibi-
tion of Mcl-1 and A1 most efficiently induced cell death in 1205Lu
melanoma cells. Without further stimulus, around 60% of
melanoma cells died whereas fibroblasts remained healthy
(Figure 3C and D). The combined inhibition of Mcl-1 and A1
was significantly more effective compared to the single inhibition
of the respective gene (Figure 4A). To reduce the probability of
siRNA off-target effects, different siRNA sequences targeting Mcl-
1 and A1 were examined. Cell death was induced in 1205Lu cells
in a similar manner (Figure 4B). To confirm apoptosis as the key
mechanism of cell death, caspase activation was analyzed.
Immunoblots demonstrated activation of the effector caspase 3
and of caspase 9, a key initiator caspase of the mitochondrial
apoptosis pathway (Figure 4C). To functionally test whether
caspases are required for cell death, the pan-caspase inhibitor
zVAD-FMK was applied. zVAD-FMK almost abolished cell
death, indicating the crucial role of caspases for cell death induced
by Mcl-1/A1 inhibition (Figure 4D).
Next, these analyses were extended to other melanoma cell lines
derived from different tumor stages and to primary human
keratinocytes, representative for another non-malignant skin cell
type. Similar to fibroblasts, keratinocytes were not sensitive to the
inhibition of Mcl-1 or A1, nor to the inhibition of both proteins
simultaneously (Figure 5A, upper left panel). In melanoma cell
lines, substantial sensitivity to Mcl-1 inhibition was observed in 3
of 5 melanoma cells, i.e., WM3211, WM1232, and WM1158
(Figure 5A, other panels). Sensitivity to A1 inhibition was observed
in 2 of 5 melanoma cell lines, i.e., WM239A, and WM1158.
WM1232 cells were found not to be sensitive to A1 inhibition
despite high A1 levels. This may be due to the lower siRNA knock-
down efficacy observed in this cell line compared to WM239A,
another cell line with high A1 level that was sensitive (Figure 5B).
However, the combined inhibition of Mcl-1 and A1 resulted in
Melanoma Cells Require Mcl-1 and A1 for Survival
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rates ranging from 60% to 80%.
Together, the results show that the combined inhibition of Mcl-
1 and A1 efficiently induces apoptosis in melanoma cell lines,
whereas primary cells remain unaffected.
Inhibition of Mcl-1 and A1 cooperates with
chemotherapy to induce cell death in 1205Lu melanoma
cells
We next examined whether cell death induced by inhibition of
A1, Mcl-1, or both, can further be enhanced by exposure to
chemotherapy, i.e., 5-fluorouracil (5-FU), while maintaining the
tumor specificity. Cells were treated with siRNAs with or without
5-FU. Three and 6 days after treatment cell viability was measured
by a fluorimetric assay and cell death induction was measured by
FACS analysis. On day 3, melanoma cell viability was decreased
by inhibition of A1 and Mcl-1, respectively, and – most
prominently – by inhibition of both (Figure 6A, left panel). This
was associated with induction of cell death as observed before
(Figure 6A, right panel). Treatment with 5-FU did not affect cell
viability or cell death at this time point. Next cells were analyzed at
a later time point on day 6 (Figure 6B). On day 6, 5-FU slightly
decreased melanoma cell viability and caused cell death in control
samples. A1 or Mcl-1 inhibition, however, reduced cell viability to
60% or 30%, respectively, at this time point, whereas inhibition of
both resulted in around 20% surviving cells. In case of treatment
with 5-FU, cell viability of Mcl-1-inhibited cells was further
reduced from 30% to around 15% and cell viability of Mcl-1/A1-
inhibited cells from 20% to 10% (Figure 6B; left panel).
Surprisingly when cell death was analyzed in the remaining
population by FACS, no apoptotic or dead cells were observed on
day 6 in A1/Mcl1-inhibited cells without 5-FU despite a strong
reduction in cell viability (Figure 6B; right panel). This suggests
that a small portion of cells seems to be unaffected by A1- or Mcl-
1-targeting siRNA treatment. However when 5-FU was applied,
cell death was significantly increased in this surviving population
(Figure 6B; right panel), ultimately leading to the reduction in total
cell viability to 10% in Mcl-1/A1-inhibited cells (Figure 6B; left
panel). In contrast to 1205Lu melanoma cells, in primary
fibroblasts no reduction of cell viability (Figure 6C; left panel)
and no increase in cell death (Figure 6C; right panel) was observed
on day 6, neither by inhibition of A1, Mcl-1, or A1/Mcl-1 alone
nor by co-administration of 5-FU. These results were confirmed
morphologically by microscopic evaluation (Figure 7).
Together, the data suggest that chemotherapy cooperates with
Mcl-1 and A1 by killing cells that survive A1 or Mcl-1 inhibition.
This results in increased cell death while tumor specificity was
maintained.
Discussion
Several studies have analyzed the levels of antiapoptotic Bcl-2
proteins in melanoma, however the results were conflicting and
the relevance of Bcl-2 molecules is still unclear [14]. In this study,
we aimed at characterizing the relevance of antiapoptotic Bcl-2
proteins in melanoma cell lines in a systematic manner. In
previous studies small peptides mimicking certain BH3-only
proteins [15] or small molecule Bcl-2 inhibitors have been used
[16]. Here, we made use of RNA interference, which enables
targeting of all Bcl-2 molecules using the same method thereby
allowing better comparison. In addition, the method allows
controlling efficacy and targeting specificity by measuring protein
or transcript abundance. With this technology we achieved
efficient silencing of Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1 without
affecting the expression of non-targeted antiapoptotic Bcl-2
members. A comparative analysis of the relevance of these
molecules was performed not only in melanoma cell lines, but
also in non-malignant cells. In a therapeutic perspective, it is very
important to specifically target cancer cells while sparing normal
cells to avoid unwanted toxicity. However, whereas in many
studies antiapoptotic Bcl-2 proteins or BH3 mimetics have been
investigated in several cancer types, comparative studies with non-
malignant cells to evaluate tumor-specific effects are surprisingly
rare. Melanocytes are the non-malignant cell type, melanoma
derives from. However, melanocytes represent a rare and
specialized cell type. In a therapeutic perspective, the targeting
of melanocytes should not harm significantly an organism as
opposed to damaging other more prevalent cells with essential
physiological functions. Therefore we considered primary fibro-
blasts, which represent an ubiquitous cell type, and keratinocytes,
which represent a mayor cell type of the skin, as a more
appropriate non-malignant reference. Furthermore, targeting of
melanocytes with RNAi-inducing agents is associated with serious
technical problems due to low knock-down efficacies, which
complicate the comparison with melanoma cells.
In this systematic screen, Mcl-1, but also A1, have been
identified as potential targets whose loss led to strong cell death
induction in melanoma cell lines, whereas non-malignant cells
remained unaffected. Inhibition of Mcl-1 effectively induced
apoptosis in most melanoma cell lines. Newly, A1 was identified
as a molecule that is of relevance for melanoma cell survival.
Despite less efficient apoptosis induction compared to Mcl-1,
combined targeting of Mcl-1 and A1 caused a substantial increase
in cell death in the majority of melanoma cell lines tested, without
inducing apoptosis in fibroblasts or keratinocytes. Nevertheless,
melanoma cell lines were identified that were primarily dependent
on Mcl-1 (WM1232) or A1 (WM239A) and the combined
treatment did not show an additional benefit. However, all
melanoma cell lines tested in our study were sensitive to at least
one of both Bcl-2 members. This demonstrates that - even in the
presence of varying expression levels and sensitivities among
melanoma cell lines - targeting of A1 at least broadens the
apoptotic sensitivity of melanoma cells to Mcl-1 inhibition. In a
therapeutic perspective, this may be important for the develop-
ment of multi-specific BH3 mimetics. The intrinsic sensitivity of
melanoma cells to Mcl-1 and A1 loss is also supported by several
studies that observed melanoma cell death that was associated with
Figure 2. Inhibition of Mcl-1 or A1 leads to melanoma-specific cell death. (A) Primary human fibroblasts and 1205Lu melanoma cells were
treated with the indicated siRNAs and expression of Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 was analyzed after 48 hours by immunoblotting. (B) A1 mRNA was
measured by quantitative RT-PCR in cells treated with A1-specific- or control siRNA for 48 hours (left and middle panel). Non-targeted Bcl-2 proteins
were analyzed at the same time point by immunoblotting (right panel). (C) Cell death of fibroblasts was determined by quantification of Annexin V
(AN)- and propidium iodide (PI)-positive cells 72 hours after transfection of the indicated siRNAs. (D) Cell death analysis of 1205Lu melanoma cells
treated as described in C. Asterisks indicate a significant increase in cell death versus control siRNA-treated cells. (E) Fluorescence-activated cell
sorting (FACS) of apoptotic and dead fibroblasts (upper panel) or 1205Lu melanoma cells (lower panel) treated as described in C. Numbers indicate
the portion of cells in each quadrant that defines Annexin V- or propidium iodide-positive or negative cells. Mean +/2 SD of at least 3 independent
experiments is shown in B, C, and D. a-tubulin served as loading control in immunoblots. Blots are representative for 3 independent experiments.
doi:10.1371/journal.pone.0030821.g002
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30821Figure 3. Melanoma-specific cell death can be enhanced by combined inhibition of Mcl-1 and A1. (A) Fibroblasts (left panel) and 1205Lu
melanoma cells (right panel) were transfected with the indicated siRNAs for 48 hours. Thereafter, 1 mM ABT-737 was added and cell death was
assessed 24 hours after ABT-737 treatment. (B) Fibroblasts were simultaneously transfected with two siRNAs as indicated. 48 hours after transfection
the respective protein was analyzed by immunoblotting (upper panels) or RT-PCR (lower panel). Blots are representative for 3 (upper left panel) or 2
(upper right panel) independent experiments. Cell death analysis of (C) fibroblasts or (D) 1205Lu melanoma cells treated with the indicated siRNAs for
72 hours. Mean +/2 SD of 3 independent experiments is shown in A, B, C and D. a-tubulin or b-actin served as loading control in immunoblots. White
lines indicate lanes that were run at the same blot but are not contiguous. Asterisks represent significant increase in cell death compared to control
siRNA-treated cells. AN, Annexin V; PI, propidium iodide.
doi:10.1371/journal.pone.0030821.g003
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specifically inactivates Mcl-1 and A1 [20].
In contrast to melanoma, inhibition of single antiapoptotic
proteins did not lead to cell death in non-malignant fibroblasts.
However, when targeting two antiapoptotic Bcl-2 proteins
simultaneously, the approach to identify tumor-specific combina-
tions turned out to be very important: Inhibition of Mcl-1 in
combination with the inhibitor ABT-737 strongly induced cell
death, which was also observed by others [21]. However, this
seems not to be restricted to tumor cells as the same treatment
induced apoptosis in fibroblasts. Similar results were also observed
upon inhibition of Mcl-1 together with Bcl-xL. This indicates that
certain combinations, despite highly efficient cell death induction,
are not advantageous for therapy because they address several cell
types leading to general toxicity. Consequently, detailed knowl-
edge of the sensitivity of the targeted cancer type with respect to
non-malignant tissue is crucial for the development and for
administration of BH3 mimetics that typically target more than
one Bcl-2 molecule.
Other studies reported that melanoma cells require Mcl-1 for
survival under certain stress conditions, like endoplasmatic
reticulum stress, lack of cell adhesion, or proapoptotic stimuli that
target the death receptor-mediated apoptotic pathway [22–24].
Interestingly, in our study inhibition of Mcl-1 and A1 efficiently
induced cell death in a panel of melanoma cell lines without
additional stimulus. An intrinsic sensitivity of melanoma cell lines
to Mcl-1 inhibition has been observed by others [24]. This
indicates that – in contrast to non-malignant cells - melanoma cells
require the presence of Mcl-1 or A1 for survival. A potential
reason for this sensitivity could be tumor cell-specific alterations:
For tumor formation, several cellular properties are necessary
which can be acquired by genetic, epigenetic, or other
modifications [25]. However, such alterations occur randomly
and are associated with other alterations that do not necessarily
provide an advantage to the tumor cell. When analyzing
antiapoptotic Bcl-2 proteins in non-malignant cells, a melano-
cyte-specific expression pattern was observed that was consistent
within 5 donors. In line with random alterations, this expression
pattern was dramatically altered in melanoma and strongly varied
between the different cell lines. Gains but also losses in expression
levels were observed and the expression profile did not follow a
strict pro-survival rule with consistent increase in antiapoptotic
molecules. As observed in our study, melanocytes express high
levels of Bcl-2 compared to other cell types of the skin [26] and no
Figure 4. Combined inhibition of Mcl-1 and A1 results in efficient induction of apoptosis in 1205Lu melanoma cells. (A) 1205Lu
melanoma cells were transfected with A1- or Mcl-1-specific siRNAs or control siRNAs as indicated. Cell death was assessed 72 hours after transfection.
Mean +/2 SD of 3 independent experiments is shown. Asterisks represent significant increase in cell death compared to single inhibition. (B) 1205Lu
melanoma cells were transfected with different siRNA sequences targeting A1 or Mcl-1 (A1b, Mcl-1b). Analysis was carried out as described in A.
Asterisks represent significant increase in cell death compared to single inhibition. Also, cell death induction by A1b, Mcl-1b, and A1b/Mcl-1b versus
control was significant (not indicated in the figure). (C) Caspase activation of 1205Lu cells treated as described in A was assessed by immunoblotting
with antibodies detecting the proform as well as the active subunits. Caspase 9 (upper panel) and caspase 3 (lower panel) were analyzed 48 hours
after transfection. (D) 1205Lu cells treated with siRNAs as described in A with or without the pan-caspase inhibitor zVAD-FMK (100 mM). Cell death
was measured 72 hours after transfection. Mean +/2 SD of 3 independent experiments is shown. Asterisks represent significant decrease in cell death
of zVAD-FMK-treated cells compared to cells not treated with zVAD-FMK. AN, Annexin V; PI, propidium iodide.
doi:10.1371/journal.pone.0030821.g004
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compared with melanoma cells [27]. In addition, loss of Bcl-2
expression in melanoma compared to benign nevi has been
observed by others [28]. On the other side, random alterations can
cause abnormalities that lead to cellular stress, which may render
tumor cells sensitive, makes them dependent on certain proteins,
and allows them to survive only under specific conditions. This
altered dependency has been termed as synthetic lethality or
oncogene addiction [10,11]. Our data argue for a cellular state in
which the survival proteins Mcl-1 and A1 are required to balance
such a tumor-associated stress in melanoma, and in which their
loss leads to cell death without additional apoptotic stimulus.
Chemotherapy represents an apoptotic stimulus that activates
apoptosis via multiple pathways and, therefore, may function
independently of the more focused effects of Mcl-1 and A1
inhibition. Despite high efficacy in cell death induction by Mcl-1
and A1 inhibition, we observed a small subpopulation of surviving
cells (around 20%). The chemotherapeutic agent 5-fluorouracil (5-
FU) resulted in significant cell death in this surviving subpopula-
tion. 5-FU reduces DNA synthesis by inhibiting thymidylate
synthase, causes DNA damage, and promotes apoptosis via the
DNA damage pathway [29]. This indicates that chemotherapy
adds to the effect caused by inhibition of Bcl-2 proteins by
targeting other apoptosis-inducing pathways.
Figure 5. Combined inhibition of Mcl-1 and A1 results in efficient induction of cell death in a panel of melanoma cell lines, but not
in keratinocytes. (A) Primary human keratinocytes (upper left panel), non-invasive melanoma cells (WM3211), invasive (WM793), and metastatic
melanoma cells (WM1232, WM239A, WM1158) were transfected with the siRNAs as indicated. Cell death was determined 72 hours after transfection.
Mean +/2 SD of 3 (keratinocytes, WM1232, WM239A, WM1158) or 5 (WM3211 and WM793) independent experiments is shown. (B) A1 mRNA was
measured by quantitative RT-PCR in indicated cells treated with A1-specific- or control siRNA for 48 hours. Mean +/2 SD of 3 independent
experiments is shown. Asterisks represent significant increase in cell death compared to control siRNA-treated cells. AN, Annexin V; PI, propidium
iodide.
doi:10.1371/journal.pone.0030821.g005
Melanoma Cells Require Mcl-1 and A1 for Survival
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30821Together, this study demonstrates that it is possible to efficiently
induce cell death specifically in melanoma cells by targeting
certain antiapoptotic Bcl-2 proteins. Targeting of more than one
Bcl-2 molecule clearly increased efficacy and broadened sensitivity
among cell lines without loosing tumor specificity. Further increase
can be achieved by the combination with chemotherapy, a
treatment that kills 90% of melanoma cell lines without affecting
non-malignant fibroblasts. These data provide a basis for future
therapeutic approaches based on targeting of Bcl-2 proteins, e.g,
by BH3 mimetics. They further underscore the importance to
address each Bcl-2 molecule specifically to ascertain that cell death
or drug sensitization is restricted to the tumor.
Materials and Methods
Reagents and antibodies
Anti–Bcl-2 (Ab-1) antibody was purchased from Merck
Biosciences (Darmstadt, Germany). Anti–Bcl-xL, anti–Bcl-w,
anti-caspase 3, anti-caspase 9, and HRP-conjugated secondary
antibodies were obtained from New England Biolabs (Berlin,
Germany). Anti-Mcl-1 (22) antibody was purchased from BD
Bioscience (Heidelberg, Germany). Anti–b-actin (AC-15) and
Anti-a-tubulin (DM1A) antibodies were obtained from Sigma-
Aldrich (Munich, Germany). PCR primers and siRNAs were
purchased from Eurofins MWG Operon (Ebersberg, Germany).
Figure 6. Chemotherapy adds to cell death induced by Mcl-1 and A1 inhibition. (A) 1205Lu melanoma cells were treated with the indicated
siRNAs together with 1 mM 5-fluorouracil (5-FU) or not (no treatment) and analyzed on day 3 after transfection. Left panel: Cell viability was
determined. Viability of control siRNA-treated cells without 5-FU treatment was set to 100%. Right panel: Cell death analysis measured by FACS after
staining with Annexin V and propidium iodide. (B) Analysis of cell viability (left panel) or cell death (right panel) of 1205Lu cells on day 6 treated as
described in A. (C) Analysis of cell viability (left panel) or cell death (right panel) of primary human fibroblasts on day 6 treated as described in A. If not
otherwise indicated, asterisks represent significant increase in cell death compared to control siRNA-treated cells. Mean +/2 SD of 3 independent
experiments is shown in A, B, and C. AN, Annexin V; PI, propidium iodide.
doi:10.1371/journal.pone.0030821.g006
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Park, Illinois). zVAD-FMK was from Bachem (Bubendorf,
Switzerland).
siRNAs
siRNAs were designed as described previously [30]. Sequences
of specific siRNAs were A1: GGAAGAAUUGUAACCAUAU,
A1b: CGGAUGUGGAUACCUAUAA, Bcl-2: GGGAGAUA-
GUGAUGAAGUA, Bcl-w: GGCAGACUUUGUAGGUUAU;
Bcl-xL: GGAACUCUAUGGGAACAAU; Mcl-1: GGCAGUCG-
CUGGAGAUUAU; and Mcl-1b: CCAUGUAGAGGACCUA-
GAA. Depicted is the 19nt portion corresponding to the sense
strand of the targeted mRNA. The sequence of the non-silencing
control siRNA (ctrl) was GCGCAUUCCAGCUUACGUA.
Cell culture
Human melanoma cell lines were a gift of M. Herlyn (Wistar
Institute, Philadelphia, Pennsylvania). All were isolated from
clinically and histologically defined lesions. Keratinocytes,
melanocytes and fibroblasts were isolated from neonatal
human foreskins. Cultivation of cells was described previously
[17].
Transfection procedures
Transfections were performed in 6-well dishes in a volume of
1 ml. To enable direct comparison of single and co-inhibition
experiments, equal amounts of siRNAs (40 nM) were trans-
fected. In single inhibition experiments, 20 nM of specific
siRNA was transfected along with 20 nM control siRNA
utilizing 1.6 ml Lipofectamine RNAiMAX (Invitrogen, Darm-
stadt, Germany) according to the manufacturer’s protocol. In
co-inhibition experiments, 20 nM of each specific siRNA was
used.
Quantification of viable cells
Viable cells were quantified in 6-well dishes by using a
fluorometric assay (CellTiter-Blue Cell Viability Assay; Promega,
Mannheim, Germany). Viable cells with intact metabolism were
identified by their ability to reduce cell-permeable resazurin to
fluorescent resorufin. Medium was replaced with 750 ml of culture
medium and 150 ml of CellTiter-Blue reagent. After 1 hour
incubation at 37uC, fluorescence was measured.
Quantification of apoptotic cells and cell death
Adherent and supernatant cells were analyzed by staining with
FITC-labeled Annexin V (Roche, Mannheim, Germany) and
propidium iodide (Sigma-Aldrich) as described previously [17].
Cells were analyzed by fluorescence-activated cell sorting (FACS)
analysis using CellQuest software (BD Bioscience).
RNA extraction and quantification
Total RNA was extracted from cells using QIAzol Lysis
Reagent (Qiagen, Hilden, Germany) as described by the
manufacturer and analyzed by quantitative RT-PCR. Reverse
transcription and quantification procedures using the LightCycler
TaqMan Master Kit (Roche) together with the Universal Probe
Library system (Roche) were described previously [17]. Relative
gene expression was expressed as a ratio of the expression level of
the gene of interest to that of hypoxanthine phosphoribosyltrans-
ferase (HPRT) RNA determined in the same sample.
Protein preparation and immunoblot analysis
Adherent and supernatant cells were lysed in buffer containing
50 mM Tris, pH 7.4, 0.25 M NaCl, 1 mM EDTA, 0.1% Triton
X-100, phosphatase inhibitors (PhosSTOP, Roche), and protease
inhibitors (Complete, Mini, EDTA-free; Roche). Gel electropho-
resis, blotting and protein detection was carried out using the Xcell
Figure 7. Representative light microscopy images of 1205Lu melanoma cells (A) or fibroblasts (B) 6 days after transfection of the
indicated siRNAs alone (upper panel) or together with 1 mM 5-FU (lower panel). Scale bar=0.5 mm.
doi:10.1371/journal.pone.0030821.g007
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[17]. Protein levels of b-actin or a-tubulin were analyzed as a
control for constant loading and transfer.
Statistics
For statistical analysis, 2-tailed Student’s t test was used to assess
the significance of mean differences. Differences were considered
significant at a P value of 0.05 or less.
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